Recent advances in molecular targeted therapy of lung cancer: Possible application in translation medicine

سال انتشار: 1403
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 81

فایل این مقاله در 12 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_IJBMS-27-2_001

تاریخ نمایه سازی: 16 دی 1402

چکیده مقاله:

Lung cancer is one of the leading causes of death among all cancer deaths. This cancer is classified into two different histological subtypes: non-small cell lung cancer (NSCLC), which is the most common subtype, and small cell lung cancer (SCLC), which is the most aggressive subtype. Understanding the molecular characteristics of lung cancer has expanded our knowledge of the cellular origins and molecular pathways affected by each of these subtypes and has contributed to the development of new therapies. Traditional treatments for lung cancer include surgery, chemotherapy, and radiotherapy. Advances in understanding the nature and specificity of lung cancer have led to the development of immunotherapy, which is the newest and most specialized treatment in the treatment of lung cancer. Each of these treatments has advantages and disadvantages and causes side effects. Today, combination therapy for lung cancer reduces side effects and increases the speed of recovery. Despite the significant progress that has been made in the treatment of lung cancer in the last decade, further research into new drugs and combination therapies is needed to extend the clinical benefits and improve outcomes in lung cancer. In this review article, we discussed common lung cancer treatments and their combinations from the most advanced to the newest.

نویسندگان

Elnaz Salmani-Javan

Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

Mahdi Farhoudi Sefidan Jadid

Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

Nosratollah Zarghami

Department of Medical Biochemistry, Faculty of Medicine, Istanbul Aydin University, Istanbul, Turkey

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, ...
  • Tokgun O, Karakas DE, Tan S, Karagür ER, İnal B, ...
  • Turner RM, Chen YW, Fernandes AW. Validation of a case-finding ...
  • Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: ...
  • Herbst RS, Morgensztern D, Boshoff C. The biology and management ...
  • Nagasaka M, Gadgeel SM. Role of chemotherapy and targeted therapy ...
  • Cai W-Q, Zeng L-S, Wang L-F, Wang Y-Y, Cheng J-T, ...
  • Su C, Ren X, Nie F, Li T, Lv W, ...
  • Hassani N, Jafari-Gharabaghlou D, Dadashpour M, Zarghami N. The effect ...
  • Xiong R, Xu RX, Huang C, De Smedt S, Braeckmans ...
  • Alagheband Y, Jafari-gharabaghlou D, Imani M, Mousazadeh H, Dadashpour M, ...
  • Islam KM, Anggondowati T, Deviany PE, Ryan JE, Fetrick A, ...
  • Sihoe AD. Video‐assisted thoracoscopic surgery as the gold standard for ...
  • Woodman C, Vundu G, George A, Wilson CM, editors. Applications ...
  • van Dorp M, Beck N, Steup WH, Schreurs WH. Surgical ...
  • Casiraghi M, Bertolaccini L, Sedda G, Petrella F, Galetta D, ...
  • Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, ...
  • Yoon SM, Shaikh T, Hallman M. Therapeutic management options for ...
  • Kobayashi N, Kobayashi K, Kikuchi S, Goto Y, Ichimura H, ...
  • Salazar MC, Rosen JE, Wang Z, Arnold BN, Thomas DC, ...
  • Duan J, Yang Z, Liu D, Shi Y. Clinical efficacy ...
  • Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, ...
  • Memmott RM, Wolfe AR, Carbone DP, Williams TM. Predictors of ...
  • Xiao Q, Zhu W, Feng W, Lee SS, Leung AW, ...
  • Huang CY, Ju DT, Chang CF, Muralidhar Reddy P, Velmurugan ...
  • Bashir D. Chemotherapy for Cancer: What It Is and How ...
  • Grewal DS. Nanotechnology as an Alternative to Chemotherapy. Int J ...
  • Sosa Iglesias V, Giuranno L, Dubois LJ, Theys J, Vooijs ...
  • Jafari-Gharabaghlou D, Dadashpour M, Khanghah OJ, Salmani-Javan E, Zarghami N. ...
  • Sooman L, Gullbo J, Bergqvist M, Bergstrom S, Lennartsson J, ...
  • Vaidya FU, Sufiyan Chhipa A, Mishra V, Gupta VK, Rawat ...
  • Katayama R. Drug resistance in anaplastic lymphoma kinase‐rearranged lung cancer. ...
  • Davoudi Z, Akbarzadeh A, Rahmatiyamchi M, Movassaghpour AA, Alipour M, ...
  • Jagodinsky JC, Harari PM, Morris ZS. The promise of combining ...
  • Mi Y, Shao Z, Vang J, Kaidar-Person O, Wang AZ. ...
  • Xu J, Gao J, Wei Q. Combination of photodynamic therapy ...
  • Formenti SC, Rudqvist NP, Golden E, Cooper B, Wennerberg E, ...
  • Chen HH, Kuo MT. Improving radiotherapy in cancer treatment: Promises ...
  • Baker S, Dahele M, Lagerwaard FJ, Senan S. A critical ...
  • Vinod SK, Hau E. Radiotherapy treatment for lung cancer: Current ...
  • Ricardi U, Badellino S, Filippi AR. Stereotactic radiotherapy for early ...
  • Berman AT, Jabbour SK, Vachani A, Robinson C, Choi JI, ...
  • Liao Z, Jiang W, Ye L, Li T, Yu X, ...
  • D’Andrea MA, Reddy GK. Systemic antitumor effects and abscopal responses ...
  • Agrawal V, Benjamin KT, Ko EC. Radiotherapy and immunotherapy combinations ...
  • Wirsdorfer F, de Leve S, Jendrossek V. Combining radiotherapy and ...
  • Hegde PS, Chen DS. Top ۱۰ challenges in cancer immunotherapy. ...
  • Hayes C. Cellular immunotherapies for cancer. Ir J Med Sci ...
  • Villanueva N, Bazhenova L. New strategies in immunotherapy for lung ...
  • Li L, Jiang M, Qi L, Wu Y, Song D, ...
  • Cella E, Zullo L, Marconi S, Rossi G, Coco S, ...
  • Schuster M, Nechansky A, Kircheis R. Cancer immunotherapy. Biotechnol J ...
  • Jain P, Jain C, Velcheti V. Role of immune-checkpoint inhibitors ...
  • Zhang H, Chen J. Current status and future directions of ...
  • Anagnostou VK, Brahmer JR. Cancer immunotherapy: A future paradigm shift ...
  • Kuol N, Stojanovska L, Nurgali K, Apostolopoulos V. The mechanisms ...
  • Creelan BC. Update on immune checkpoint inhibitors in lung cancer. ...
  • Farran B, Pavitra E, Kasa P, Peela S, Rama Raju ...
  • Kaur K, Khatik GL. Cancer immunotherapy: An effective tool in ...
  • Schutz F, Marme F, Domschke C, Sohn C, von Au ...
  • Dillman RO, Fogel GB, Cornforth AN, Selvan SR, Schiltz PM, ...
  • Rezaei T, Davoudian E, Khalili S, Amini M, Hejazi M, ...
  • Ding Y, Li Z, Jaklenec A, Hu Q. Vaccine delivery ...
  • Roy S, Sethi TK, Taylor D, Kim YJ, Johnson DB. ...
  • Truong C-S, Yoo SY. Oncolytic vaccinia virus in lung cancer ...
  • Heidary F, Tourani M, Hejazi-Amiri F, Khatami SH, Jamali N, ...
  • Zhong R, Ling X, Cao S, Xu J, Zhang B, ...
  • Huang T, Peng L, Han Y, Wang D, He X, ...
  • Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, ...
  • Oliveres H, Caglevic C, Passiglia F, Taverna S, Smits E, ...
  • Corrales L, Scilla K, Caglevic C, Miller K, Oliveira J, ...
  • Onoi K, Chihara Y, Uchino J, Shimamoto T, Morimoto Y, ...
  • Van Coillie S, Wiernicki B, Xu J. Molecular and cellular ...
  • Zhang A, Ren Z, Tseng K-F, Liu X, Li H, ...
  • Rotte A. Combination of CTLA-۴ and PD-۱ blockers for treatment ...
  • Santini FC, Hellmann MD. PD-۱/PD-L۱ axis in lung cancer. Cancer ...
  • Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, ...
  • Zheng M, Huang J, Tong A, Yang H. Oncolytic viruses ...
  • Zendedel E, Atkin SL, Sahebkar A. Use of stem cells ...
  • Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: A new ...
  • Hemminki O, Dos Santos JM, Hemminki A. Oncolytic viruses for ...
  • Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, ...
  • Ghasemi Darestani N, Gilmanova AI, Al-Gazally ME, Zekiy AO, Ansari ...
  • Mazza V, Cappuzzo F. Immunotherapy and lung cancer: From therapeutic ...
  • Escribese MM, Barber D. New insight into cancer immunotherapy. Allergol ...
  • Yuzhakova DV, Shirmanova MV, Sergeeva TF, Zagaynova EV, Lukyanov KA. ...
  • Parakh S, King D, Gan HK, Scott AM. Current development ...
  • Carter BW. Immunotherapy in lung cancer and the role of ...
  • Dong J, Li B, Zhou Q, Huang D. Advances in ...
  • Kakimi K, Matsushita H, Murakawa T, Nakajima J. Gammadelta T ...
  • Carter BW, Halpenny DF, Ginsberg MS, Papadimitrakopoulou VA, de Groot ...
  • Rusch T, Bayry J, Werner J, Shevchenko I, Bazhin AV. ...
  • McFarland DC. New lung cancer treatments (immunotherapy and targeted therapies) ...
  • Pinheiro FD, Teixeira AF, de Brito BB, da Silva FAF, ...
  • Aalipour S, Zoghi S, Khalili N, Hirbod-Mobarakeh A, Emens LA, ...
  • Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: Treating ...
  • Alibakhshi A, Ranjbari J, Pilehvar-Soltanahmadi Y, Nasiri M, Mollazade M, ...
  • Sechler M, Cizmic AD, Avasarala S, Van Scoyk M, Brzezinski ...
  • Lamarca A, Barriuso J, McNamara MG, Valle JW. Molecular targeted ...
  • Passaro A, Jänne PA, Mok T, Peters S. Overcoming therapy ...
  • Zhang Z, Stiegler AL, Boggon TJ, Kobayashi S, Halmos B. ...
  • Ke X, Shen L. Molecular targeted therapy of cancer: The ...
  • Mayekar MK, Bivona TG. Current landscape of targeted therapy in ...
  • Yuan M, Huang LL, Chen JH, Wu J, Xu Q. ...
  • Francis H, Solomon B. The current status of targeted therapy ...
  • Chan SK, Gullick WJ, Hill ME. Mutations of the epidermal ...
  • Riely GJ, Marks J, Pao W. KRAS mutations in non-small ...
  • Morgillo F, Della Corte CM, Fasano M, Ciardiello F. Mechanisms ...
  • Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, ...
  • Offin M, Rizvi H, Tenet M, Ni A, Sanchez-Vega F, ...
  • Dong R-F, Zhu M-L, Liu M-M, Xu Y-T, Yuan L-L, ...
  • Murtuza A, Bulbul A, Shen JP, Keshavarzian P, Woodward BD, ...
  • Papadimitrakopoulou VA, Mok TS, Han JY, Ahn MJ, Delmonte A, ...
  • Mitsudomi T. Advances in target therapy for lung cancer. Jpn ...
  • Diaz-Serrano A, Gella P, Jimenez E, Zugazagoitia J, Paz-Ares Rodriguez ...
  • Patel H, Pawara R, Ansari A, Surana S. Recent updates ...
  • Shi P, Oh YT, Zhang G, Yao W, Yue P, ...
  • Carmeliet P. VEGF as a key mediator of angiogenesis in ...
  • Waldner MJ, Neurath MF. Targeting the VEGF signaling pathway in ...
  • Alevizakos M, Kaltsas S, Syrigos KN. The VEGF pathway in ...
  • Majidpoor J, Mortezaee K. Angiogenesis as a hallmark of solid ...
  • Frezzetti D, Gallo M, Maiello MR, D’Alessio A, Esposito C, ...
  • Zarghami N, Grass L, Sauter ER, Diamandis EP. Prostate-specific antigen ...
  • Liu L, Zhang Y, Wei J, Chen Z, Yu J. ...
  • Wang R, Luo Z, Zhang H, Wang T. Tanshinone IIA ...
  • Cascone T, Xu L, Lin HY, Liu W, Tran HT, ...
  • Shaw AT, Engelman JA. ALK in lung cancer: Past, present, ...
  • Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, ...
  • Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, ...
  • Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, ...
  • Lu S, Lu C, Xiao Y, Zhu W, He Q, ...
  • Wu J, Savooji J, Liu D. Second- and third-generation ALK ...
  • Tao H, Shi L, Zhou A, Li H, Gai F, ...
  • Horn L, Pao W. EML۴-ALK: Honing in on a new ...
  • Elliott J, Bai Z, Hsieh SC, Kelly SE, Chen L, ...
  • Tomasini P, Egea J, Souquet-Bressand M, Greillier L, Barlesi F. ...
  • Karachaliou N, Fernandez Bruno M, Bracht JWP, Rosell R. Profile ...
  • Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, ...
  • Ghimessy A, Radeczky P, Laszlo V, Hegedus B, Renyi-Vamos F, ...
  • Amanam I, Mambetsariev I, Gupta R, Achuthan S, Wang Y, ...
  • Yang H, Liang SQ, Schmid RA, Peng RW. New horizons ...
  • Kempf E, Rousseau B, Besse B, Paz-Ares L. KRAS oncogene ...
  • Molina-Arcas M, Moore C, Rana S, Van Maldegem F, Mugarza ...
  • Rossi A. Alectinib for ALK-positive non-small-cell lung cancer. Expert Rev ...
  • Awad MM, Liu S, Rybkin, II, Arbour KC, Dilly J, ...
  • Roman M, Baraibar I, Lopez I, Nadal E, Rolfo C, ...
  • Gurtner K, Kryzmien Z, Koi L, Wang M, Benes CH, ...
  • Riudavets M, Sullivan I, Abdayem P, Planchard D. Targeting HER۲ ...
  • Ni J, Zhang L. Progress in Treatment of Non-Small Cell ...
  • Zhao S, Xian X, Tian P, Li W, Wang K, ...
  • Mar N, Vredenburgh JJ, Wasser JS. Targeting HER۲ in the ...
  • Bondili SK, Nandhana R, Noronha V, Pawar S, Menon N, ...
  • Alvarez JGB, Otterson GA. Agents to treat BRAF-mutant lung cancer. ...
  • Roviello G, D’Angelo A, Sirico M, Pittacolo M, Conter FU, ...
  • Yan N, Guo S, Zhang H, Zhang Z, Shen S, ...
  • Leonetti A, Facchinetti F, Rossi G, Minari R, Conti A, ...
  • Li M, Zhang X. BRAF mutations and resistance of non-small ...
  • Araujo JM, Gomez AC, Pinto JA, Rolfo C, Raez LE. ...
  • Azelby CM, Sakamoto MR, Bowles DW. ROS۱ targeted therapies: current ...
  • Bubendorf L, Buttner R, Al-Dayel F, Dietel M, Elmberger G, ...
  • Roys A, Chang X, Liu Y, Xu X, Wu Y, ...
  • Choudhury NJ, Schneider JL, Patil T, Zhu VW, Goldman DA, ...
  • Wu YL, Soo RA, Locatelli G, Stammberger U, Scagliotti G, ...
  • Liang H, Wang M. MET oncogene in non-small cell lung ...
  • Yu J, Zhang L, Peng J, Ward R, Hao P, ...
  • Oh HN, Kwak AW, Lee MH, Kim E, Yoon G, ...
  • Faiella A, Riccardi F, Carteni G, Chiurazzi M, Onofrio L. ...
  • Miranda O, Farooqui M, Siegfried JM. Status of agents targeting ...
  • Prasad RR, Mishra DK, Kumar M, Yadava PK. Human telomerase ...
  • نمایش کامل مراجع